Anuwatmatee S, et al. - Given fibroblast growth factor 21 (FGF21) may play a role in the development of chronic kidney disease (CKD), researchers explored the association of plasma FGF21 levels with kidney function and albuminuria in the Multi-Ethnic Study of Atherosclerosis (MESA). They analyzed the MESA participants ages 45–84 years between 2000 and 2002, free of clinically apparent cardiovascular disease (CVD). During four additional clinic visits over 10 years, participants were followed up in person. In adults free of clinically apparent CVD at baseline, a role of FGF21 as a biomarker for predicting kidney function decline or albuminuria was not supported.